Route of Administration and Bioavailability: What Actually Determines Absorption

The same peptide, at the same dose, doesn't produce the same result if you change how it's administered. Route of administration is one of the most concrete, well-understood levers in pharmacokinetics — and understanding why it matters starts with a single concept: bioavailability.

Bioavailability is a fraction, not a formality

Bioavailability, usually written as F, is the fraction of an administered dose that actually reaches general circulation intact. An intravenous dose has, essentially by definition, 100% bioavailability — the compound is placed directly into the bloodstream, with nothing to absorb through. Every other route has to get the compound from an administration site into circulation, and that journey isn't lossless.

In the underlying pharmacokinetic model, bioavailability multiplies the dose directly: C(t) = Dose · F · (rest of the absorption/elimination math). A route with F = 0.5 produces, all else equal, half the peak concentration of a route with F = 1.0 — not a subtle difference, a linear, direct one.

Why molecular size drives so much of this

For peptides specifically, one of the biggest single factors determining bioavailability by route is molecular weight. Peptides are, generally speaking, too large to passively cross certain membranes efficiently — which is exactly why so many peptides are injected rather than swallowed. Oral bioavailability for larger peptides tends to be very low, because digestive enzymes and the gut wall present real barriers that shrink dramatically as molecular size increases. Nasal and sublingual routes fare somewhat better than oral for the same reason mucosal absorption partially sidesteps first-pass digestion, but the same general size relationship still applies: larger molecules cross less efficiently than smaller ones, on any absorption route that isn't a direct injection.

This isn't a fine, continuous curve where every gram/mol matters — real-world bioavailability differences by route tend to cluster into rough tiers rather than smoothly scaling with tiny weight differences. A coarse, tiered model of "large peptides absorb poorly by mouth or nose, small molecules absorb dramatically better" reflects the actual pattern more honestly than pretending there's precision down to the individual dalton that available data simply doesn't support.

Subcutaneous and intramuscular injection largely sidestep this problem — both routes achieve high bioavailability regardless of a peptide's size, because the compound is placed directly into tissue with a rich blood or lymphatic supply, not asked to cross a digestive or mucosal barrier at all.

Absorption rate is a separate question from absorption completeness

Bioavailability answers "how much gets in eventually." Absorption rate — the ka term in the underlying model — answers a different question: "how fast." These aren't the same thing, and route affects both, sometimes in different directions. A subcutaneous injection, going into fatty tissue with a comparatively modest blood supply, tends to absorb more slowly than an intramuscular injection into a well-vascularized muscle — which is part of why the same compound's curve, by route, is typically described as "SC peaks broader and later, IM peaks sharper and sooner," even when both routes deliver a similar total amount into circulation.

Why this belongs in a tracking tool at all

None of this is included to suggest one route is generically "better" — that's a decision made in a completely different, individualized, non-generalizable context that a piece of software has no business making for anyone. It's included because route of administration is one of the few genuinely well-characterized, mechanistic factors that changes what a plasma-level curve should actually look like — and a modeling tool that ignored it, and simply drew the same curve shape regardless of how a dose was actually taken, would be quietly throwing away real information rather than modeling it. Letting the underlying math account for route honestly is what keeps the resulting curve grounded in how absorption actually works, rather than being a generic shape stretched to fit whatever was logged.